Compare ACADIA Pharmaceuticals Inc. (ACAD) vs KE Holdings Inc (BEKE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs KE Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while KE Holdings Inc trades at $15.34 (market cap $16.40B). The key difference: KE Holdings Inc is far larger — about 3.7× ACADIA Pharmaceuticals Inc.'s market cap, and KE Holdings Inc pays a 1.86% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BEKE | |
|---|---|---|
Market Cap | $4.49B | $16.40B |
Sector | Health | Technology |
52-Week High | $28.06 | $20.36 |
52-Week Low | $20.06 | $14.26 |
Enterprise Value | $3.69B | $12.17B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BEKE trades at $15.02, down 0.46% with a bearish technical signal. The company reported strong Q1 2026 earnings beating expectations with EPS of $0.20 versus $0.14 expected, driven by improved profitability despite lower revenue. Analyst sentiment remains overwhelmingly positive with 91.7% buy ratings. Recent news highlights potential trend reversal opportunities after a 14.1% decline over four weeks.
The outlook suggests potential upside with improving operational efficiency and cost controls offsetting market softness. Key risks include China's property market volatility and competitive pressures. With strong institutional support and positive earnings momentum, BEKE presents a compelling growth story despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →
